FCF Life Sciences
Venture Capital Monitor
-
Europe

The FCF Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.

FCF Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous
Next

As of the end of April 2021, we identify the following current VC trends in Europe:

  • In 2021, overall Life Sciences funding has reached EUR 4,288m so far
  • Top 5 Deals exceed EUR 140m each, largest transaction amounted to EUR 253m in Kry International AB (Sweden)
  • BlackRock (USA) still dominates the Top 5 Investors (by deal volume), followed by Fidelity Management & Research (USA) and Novo Holdings (Denmark)
  • The Biotechnology sector received 65% of the total investment volume (-11% points compared to the previous month)
  • Central Nervous System replaces Oncology as the top indication
FCF Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous
Next

RESEARCH

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

Licensing

Recent licensing trends of European Biotech companies in China
Upcoming
Recent licensing trends of European Biotech companies in China
Upcoming

Biotech Licensing Monitor – China
-Upcoming-
Recent licensing trends of European Biotech companies in China

NEWS & PRESS

Scroll Up